Clinical trial · Interventional
Engineering Immune Organoids to Study Pediatric Cancer
Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)
NCT05890781CI-TRIAL-00102842IMMUNEORGANOIDrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
| Kidney Tumor | Kidney Neoplasm | ALIAS | 0.90 |
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Biological | — | UNRESOLVED |
| Fresh tumor sample | Procedure | — | UNRESOLVED |
| Healthy tissue from the tumor | Procedure | — | UNRESOLVED |
| Skin biopsy | Procedure | — | UNRESOLVED |
| Spinal cerebrospinal fluid (SCF) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Immune organoids from pediatric patient tissues using iPSC
- description
- To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
- interventionNames
- Procedure: Skin biopsy
- Procedure: Fresh tumor sample
- Biological: Blood sample
- Procedure: Healthy tissue from the tumor
- Procedure: Spinal cerebrospinal fluid (SCF)
Primary outcomes (1)
- measure
- Proportion of viable and exploitable immune organoids with engrafted tumor cells
- timeFrame
- until 5 years after enrolment
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied * Medical suspicion or diagnosis of one of the following diseases, regardless of stage: * Brain tumors * Renal tumors * Neuroblastoma * Sarcomas * Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol. * Affiliated to a social security system or beneficiary of the same. Exclusion Criteria: * Any histology not mentioned in the inclusion criteria * Adult patient or parents/guardians incapable/incapable of giving its/their consent * Patients deprived of their liberty by a judicial or administrative decision
References
Publications (0)
Data not yet available
No reference posted for this study.